GlassScriptPhysician profile
Ray I Georgeson
NPI 1366434862
$6,648.50
in general payments reported to CMS, 2019-2025
22 companies · $1,915 in 2025
The $1,915 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $59.31 · 2021: $128 · 2022: $318 · 2023: $2,262 · 2024: $1,535 · 2025: $1,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,045 · Food and Beverage: $1,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,045.13 |
| Food and Beverage | $1,667.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,898.20 | 2019-2025 | Aveir, Tendril, Cardiomems |
| Novartis Pharmaceuticals Corporation | $441.94 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $193.65 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $176.58 | 2022-2025 | Farxiga |
| Pfizer INC. | $136.04 | 2022-2025 | |
| Novo Nordisk INC | $127.28 | 2019-2024 | Wegovy |
| Amgen INC. | $107.23 | 2025 | Repatha |
| Edwards Lifesciences Corporation | $56.17 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $53.55 | 2020-2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $52.42 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $51.41 | 2019-2025 | Dupixent |
| Arbor Pharmaceuticals, INC. | $50.43 | 2019-2020 | |
| Cvrx, INC. | $44.68 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $41.09 | 2024 | Arcalyst |
| Boston Scientific Corporation | $39.35 | 2024-2025 | Watchman Flx, General - Pain Management |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.94 | 2024-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.59 | 2019-2025 | Jardiance |
| Cardiovascular Systems INC. | $26.40 | 2022 | |
| Baxter Healthcare | $24.75 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Philips North America LLC | $20.74 | 2022 | |
| Tactile Systems Technology INC | $19.93 | 2023 | Flexitouch Plus, Entre Plus |
| Siemens Medical Solutions USA, INC. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Georgeson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.